The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Interim analysis of a single-arm, phase II study of bevacizumab (BV) with modified OPTIMOX1 as first-line treatment of patients with metastatic colorectal cancer (mCRC): TCOG-GI0802.
Michio Asano
Disclosure not yet available
Soichi Tanaka
Disclosure not yet available
Atsushi Sato
Disclosure not yet available
Norisuke Nakayama
Disclosure not yet available
Ken Shimada
Disclosure not yet available
Kazuo Konishi
Disclosure not yet available
Kenji Hibi
Disclosure not yet available
Eisaku Sasaki
Disclosure not yet available
Minoru Kurihara
Disclosure not yet available